Table 2

AKI outcomes in the SGLT2 inhibitor user and nonuser groups in the Mount Sinai and Geisinger propensity-matched cohorts

Mount Sinai cohortGeisinger cohort
User (n = 372)Nonuser (n = 372)P1User (n = 1,207)Nonuser (n = 1,207)P2
AKIKDIGO–inpatient14 (3.8)36 (9.7)0.00226 (2.2)55 (4.6)0.001
AKIICD22 (5.9)40 (10.8)0.0215 (1.2)36 (3.0)0.003
Peak creatinine in AKIKDIGO events1.6 (1.4–1.8)1.9 (1.6–2.4)0.021.7 (1.4–2.6)1.6 (1.3–2.4)0.91
Change in serum creatinine during AKIKDIGO events0.5 (0.4–0.7)0.9 (0.8–1.3)0.0040.6 (0.5–1.0)0.6 (0.4–1.2)0.80
Need for acute dialysis1 (0.3)1 (0.3)1.000 (0.0)1 (0.1)0.317
  • P1 and P2 are P values for primary and secondary analyses, respectively.